Gretchen Poortinga

St. Andrews Place
East Melbourne, VIC 3002, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Journal: medRxiv : the preprint server for health sciences

Published: November 19, 2025

CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci.

CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci.

Journal: Biomedicines

Published: May 30, 2024

Targeting the ribosome to treat multiple myeloma.

Targeting the ribosome to treat multiple myeloma.

Journal: Molecular therapy. Oncology

Published: November 30, 2023

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.

Journal: The EMBO journal

Published: March 26, 2020

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.

Journal: Frontiers in cell and developmental biology

Published: December 16, 2019

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 24, 2019

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

Journal: Nature communications

Published: June 28, 2019

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Journal: Cancer discovery

Published: December 12, 2018

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Journal: Communications biology

Published: March 04, 2018

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Journal: International journal of cancer

Published: July 03, 2017

Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.

Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.

Journal: PLoS neglected tropical diseases

Published: September 14, 2016

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Journal: Blood

Published: May 24, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026